Overview

Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer

Status:
Completed

Trial end date:
2016-05-01

Target enrollment:

Participant gender:

Summary

This phase II trial studies how well giving irinotecan hydrochloride together with oxaliplatin and capecitabine works as first-line therapy in treating patients with metastatic or unresectable locally advanced small bowel cancer. Drugs used in chemotherapy, such as irinotecan hydrochloride, oxaliplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

Phase:

Phase 2

Details

Lead Sponsor:

Alliance for Clinical Trials in Oncology

Collaborators:

National Cancer Institute (NCI)
Pfizer
Sanofi

Treatments:

Camptothecin
Capecitabine
Irinotecan
Oxaliplatin